Current Diagnosis and Management of Graves’ Disease

Imam Subekti, Laurentius Aswin Pramono

Abstract


Graves’ disease is an autoimmune disorder which affect thyroid gland. Graves’ disease is the most common cause of hyperthyroidism and thyrotoxicosis. Understanding of disease pathophysiology, diagnostic and treatment strategies, and prevention of disease relapse are important for all clinicians especially internal medicine specialist to give optimal and comprehensive management for Graves’ disease patients. This article highlights clinical points to treat Grave’s disease patients from reviews and latest guidelines from American Thyroid Association (ATA), European Thyroid Association (ETA), and Japan Thyroid Association/ Japan Endocrine Society.

Keywords


Grave's disease; thyroid; American Thyroid Association (ATA); European Thyroid Association (ETA); Japan Thyroid Association/ Japan Endocrine Society

References


Weetman AP. Graves' disease. N Eng J Med. 2000;343(17):1236-48.

Barnett PS, McGregor AM. Immunological factors. In Disease of The Thyroid: pathophysiology and management. Wheeler MH dan Lazarus JH (eds). Chapman & Hall Medical. Cambridge UK, 1994; p. 85-103.

Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves’ disease. Trend in Endocrinol Metab. 2005;16(5):243-8.

Subekti I. Diagnosis dan pengelolaan oftalmopati Graves. Dalam Jakarta Endocrinology Meeting. Divisi Metabolik Endokrinologi, Departemen Ilmu Penyakit Dalam FKUI/RSCM Jakarta.2008:30-5.

Drexhage HA. Are there more than antibodies to the thyroid stimulating hormone receptor that meet the eye in Graves’ disease. Endocrinol. 2006;147(1):9-12.

Brent GA. Graves’ Disease. N Engl J Med. 2008;358:2594-605.

Ross DS, Burch HB, Cooper DS, Greenlee C, Laurberg P, Maia AL, Rivkees SA, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 10:1343-421.

Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017; 27(10):1223-31.

Rubio GA, Sengul TK, Vaghaiwalla TM, Parikh PP, Farra JC, Lew JI. Postoperative outcomes in Graves’ disease patients: results from the nationwide inpatient sample database. Presented at the 86th Annual Meeting of the American Thyroid Association, Denver, CO, September 21-25, 2016.

Struja T, Tehlberg H, Kutz A, Guebelin L, Degen C, Mueller B, et al. Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017; 176:87-97.

Eliana F, Soewondo P, Asmarinah, Harahap A, Djauzi S, Prihartono J, et al. The role of cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) gene, Thyroid Stimulating Hormone Receptor (TSHR) gene and regulatory T-cells as risk factors for relapse in patients with Graves’ disease. Acta Med Indones – Indones J Intern Med. 2017;49(3):195-204.

Liu J, Fu J, Xu Y, Wang G. Anti-thyroid drug therapy for Graves’ disease and implications for recurrence. Int J Endocrinol. 2017;1-8.

Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (first edition). Endocrine J. 2016;63(12):1025-64.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016; 5:9-26.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Acta Medica Indonesiana